These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19492089)

  • 1. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.
    Kvam E; Nannenga BL; Wang MS; Jia Z; Sierks MR; Messer A
    PLoS One; 2009 May; 4(5):e5727. PubMed ID: 19492089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
    Lecerf JM; Shirley TL; Zhu Q; Kazantsev A; Amersdorfer P; Housman DE; Messer A; Huston JS
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4764-9. PubMed ID: 11296304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aging causes distinct characteristics of polyglutamine amyloids in vivo.
    Tonoki A; Kuranaga E; Ito N; Nekooki-Machida Y; Tanaka M; Miura M
    Genes Cells; 2011 May; 16(5):557-64. PubMed ID: 21466635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel polyglutamine model uncouples proteotoxicity from aging.
    Christie NT; Lee AL; Fay HG; Gray AA; Kikis EA
    PLoS One; 2014; 9(5):e96835. PubMed ID: 24817148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein.
    Ellisdon AM; Pearce MC; Bottomley SP
    J Mol Biol; 2007 Apr; 368(2):595-605. PubMed ID: 17362987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis.
    Ricchelli F; Fusi P; Tortora P; Valtorta M; Riva M; Tognon G; Chieregato K; Bolognin S; Zatta P
    Int J Biochem Cell Biol; 2007; 39(5):966-77. PubMed ID: 17300980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p62/sequestosome 1 regulates aggresome formation of pathogenic ataxin-3 with expanded polyglutamine.
    Zhou L; Wang H; Chen D; Gao F; Ying Z; Wang G
    Int J Mol Sci; 2014 Aug; 15(9):14997-5010. PubMed ID: 25158237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes.
    Jana NR; Dikshit P; Goswami A; Kotliarova S; Murata S; Tanaka K; Nukina N
    J Biol Chem; 2005 Mar; 280(12):11635-40. PubMed ID: 15664989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temperature-dependent, irreversible formation of amyloid fibrils by a soluble human ataxin-3 carrying a moderately expanded polyglutamine stretch (Q36).
    Shehi E; Fusi P; Secundo F; Pozzuolo S; Bairati A; Tortora P
    Biochemistry; 2003 Dec; 42(49):14626-32. PubMed ID: 14661975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
    Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
    Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.
    Nozaki K; Onodera O; Takano H; Tsuji S
    Neuroreport; 2001 Oct; 12(15):3357-64. PubMed ID: 11711886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PolyQ-expanded proteins impair cellular proteostasis of ataxin-3 through sequestering the co-chaperone HSJ1 into aggregates.
    Yue HW; Hong JY; Zhang SX; Jiang LL; Hu HY
    Sci Rep; 2021 Apr; 11(1):7815. PubMed ID: 33837238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step.
    Ellisdon AM; Thomas B; Bottomley SP
    J Biol Chem; 2006 Jun; 281(25):16888-16896. PubMed ID: 16624810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The composition of the polyglutamine-containing proteins influences their co-aggregation properties.
    Bak D; Milewski M
    Cell Biol Int; 2010 Sep; 34(9):933-42. PubMed ID: 20515443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease.
    Chow MK; Paulson HL; Bottomley SP
    J Mol Biol; 2004 Jan; 335(1):333-41. PubMed ID: 14659761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence.
    Ignatova Z; Thakur AK; Wetzel R; Gierasch LM
    J Biol Chem; 2007 Dec; 282(50):36736-43. PubMed ID: 17942400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.
    Lynch SM; Zhou C; Messer A
    J Mol Biol; 2008 Mar; 377(1):136-47. PubMed ID: 18237741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interactions as a survival strategy against abnormal aggregation.
    Masino L; Nicastro G; Calder L; Vendruscolo M; Pastore A
    FASEB J; 2011 Jan; 25(1):45-54. PubMed ID: 20810784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.